NCT05214612 Predictors and Prognostic Factors of Myasthenia Gravis Outcome
| NCT ID | NCT05214612 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assiut University |
| Condition | Myasthenia Gravis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2022-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.
Eligibility Criteria
Inclusion Criteria: 1. Age from 16 years and older. 2. Gender: both sexes are included. 3. Clinical Diagnosis of MG with supporting evidence as: 1. unequivocal clinical response to pyridostigmine 2. decrement \>10% in repetitive nerve stimulations study (RNS). 4. Willingness to sample collection, imaging study and other disease-related examinations and assessments. Exclusion Criteria: 1. Age younger than 16 years. 2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue. 3. Severe systemic illness affecting life-expectancy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05214612 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Myasthenia Gravis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05214612 currently recruiting?
Yes, NCT05214612 is actively recruiting participants. Contact the research team at nourelhodaahmed@aun.edu.eg for enrollment information.
Where is the NCT05214612 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT05214612 clinical trial?
NCT05214612 is sponsored by Assiut University. The trial plans to enroll 30 participants.